Clinical Trials on Advanced/ Metastatic Renal Cell Cancer in United Kingdom

Total 9382 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Royal Marsden NHS Foundation Trust

Completed

A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx

Locally Advanced Larynx, Hypopharyngeal Squamous Cell Cancers | Locally Advanced Thyroid Cancers

United Kingdom
Ipsen

Completed

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors (US NIS Cabo)

Locally Advanced or Metastatic Renal Cell Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Terminated

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Clear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7

United States
Bradley A. McGregor, MD
Bristol-Myers Squibb; Exelixis

Recruiting

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Renal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell Carcinoma

United States
Calico Life Sciences LLC
AbbVie

Recruiting

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Advanced Solid Tumors Cancer

Korea, Republic of, Taiwan, Spain, United States, France, Japan, Israel
Semafore Pharmaceuticals
SignalRX Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)

Cancer | Advanced or Metastatic Solid Tumors | Solid Cancers

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca

Recruiting

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID)

Kidney Cancer | Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Kidney Cancer Metastatic | Renal Carcinoma

United States
Pfizer

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6)

Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Korea, Republic of, Japan
Duke University
Prostate Cancer Foundation; Janssen Diagnostics, LLC

Completed

Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)

Renal Cell Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Advanced MET Amplified Solid Tumor

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

M8891 First in Human in Solid Tumors (M8891)

Metastatic Renal Cell Carcinoma | Advanced Solid Tumors

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment (IO-PAZ)

Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

Spain, Germany, United States, Austria, Czechia, United Kingdom, Argentina, Hungary, France, Canada, Chile
Ipsen

Completed

Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination (CARINA)

Advanced Renal Cell Carcinoma (aRCC)

United Kingdom
National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Royal Marsden NHS Foundation Trust

Unknown

A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR) (ADAPTeR)

Renal Cell Carcinoma

United Kingdom
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...

United States
Duke University

Terminated

Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer

Advanced Cancer | Brain Metastasis | Metastatic Cancer Patients on an Anti-cancer Therapy

United States
AstraZeneca

Completed

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients (BEECH)

Advanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast Cancer

Canada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
Immodulon Therapeutics Ltd

Terminated

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (MODULATE)

Metastatic Cancer

France, United Kingdom
M.D. Anderson Cancer Center

Active, not recruiting

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Malignant Solid Neoplasm | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Metastatic Melanoma | Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Unresectable Melanoma | Clinical Stage III Cutaneous... and other conditions

United States
Fundación de Investigación Biomédica - Hospital...
Marcello Di Martino

Completed

Chemotherapy for Resectable Colorectal Liver Metastases

Metastatic Colorectal Cancer | Metastatic Liver Cancer

Spain, United Kingdom, France
MedImmune LLC

Completed

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

Kidney Cancer | Clear Cell Renal Cell Carcinoma | Select Advanced Malignancies

United States, France, Canada, United Kingdom, Netherlands, Australia
University of Manchester
Manchester University NHS Foundation Trust; The Christie NHS Foundation Trust; Perspect... and other collaborators

Unknown

Colorectal Liver Metastases: Novel Assessment Tools for Technical Resectability (CoNoR)

Cancer | Colorectal Cancer | Liver Metastasis Colon Cancer | Cancer Metastatic

United Kingdom
NiKang Therapeutics, Inc.

Recruiting

A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Kidney Cancer | Kidney Neoplasms | Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Hypoxia | Metastatic Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Renal Cancer | Advanced Renal Cell Carcinoma | Renal Neoplasms | ccRCC | Refractory Renal Cell Carcinoma | Hypoxia Inducible Factor (HIF) | HIF2α... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Metastatic Clear Cell Renal Cell Carcinoma | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
Yousef Zakharia
Pfizer

Active, not recruiting

SLM + Axitinib for Clear Cell RCC

Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)

United States
Rexahn Pharmaceuticals, Inc.

Terminated

Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer

Metastatic Renal Cell Cancer

United States
Eli Lilly and Company

Completed

A Phase 1b Trial in Patients With Renal Cell Cancer

Metastatic Renal Cell Cancer

United States, Canada
Novartis Pharmaceuticals

Completed

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Metastatic Breast Cancer (MBC) | Locally Advance Breast Cancer (LABC)

United Kingdom, Spain
Eli Lilly and Company

Completed

A Study of LY3076226 in Participants With Advanced or Metastatic Cancer

Metastatic Cancer | Advanced Cancer

United States, Canada
Allogene Therapeutics

Recruiting

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (TRAVERSE)

Advanced/Metastatic Clear Cell Renal Cell Carcinoma

United States
University of California, San Francisco
Prostate Cancer Foundation; Strata Oncology

Active, not recruiting

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Prostate Cancer | Advanced Renal Cell Carcinoma | Genitourinary Cancer | Advanced Urothelial Carcinoma

United States
Daiichi Sankyo Co., Ltd.

Recruiting

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Solid Tumor | Metastatic Solid Tumor | Advanced Cancer

Japan, United States, Canada
M.D. Anderson Cancer Center

Recruiting

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Malignant Solid Neoplasm | Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage... and other conditions

United States
AstraZeneca

Completed

Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR)

Advanced and Metastatic Breast Cancer

United States, United Kingdom
University Hospital Southampton NHS Foundation...
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust

Unknown

Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients (EMBRACE)

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer Metastatic

United Kingdom
Cancer Research UK
Bicycle Therapeutics

Completed

BT1718 in Patients With Advanced Solid Tumours.

Non-Small Cell Lung Cancer | Advanced Solid Tumours | Oesophageal Cancer | Non-Small Cell Lung Sarcoma

United Kingdom
Gilead Sciences
Everest Medicines

Active, not recruiting

Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)

Locally Advanced or Metastatic Unresectable Urothelial Cancer

United States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
Eli Lilly and Company

Withdrawn

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Metastatic Squamous Non-Small Cell Lung Cancer | Locally Advanced Squamous Non-Small Cell Lung Cancer

Italy, Romania, Germany, Belgium, Russian Federation, United States, United Kingdom
Monopteros Therapeutics Inc.

Recruiting

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | Solid Tumor, Adult | Refractory Cancer

United States
National Cancer Institute (NCI)

Completed

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Ipsen

Active, not recruiting

Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (CaboPoint)

Locally Advanced or Metastatic Renal Cell Carcinoma

Spain, France, United Kingdom, Switzerland, Germany, Netherlands, Austria
Abramson Cancer Center of the University of Pennsylvania

Completed

RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers

Metastatic Cancers

United States
Lupin Ltd.

Completed

A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

United Kingdom, Netherlands, Belgium
Incyte Biosciences International Sàrl

Completed

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

Metastatic Cancer | Advanced Malignancies

United States, United Kingdom, Spain, Switzerland
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Perception of Cure Among Patients With Metastatic Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Novartis Pharmaceuticals

No longer available

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Metastatic Renal Cell Cancer

United States, United Kingdom, Czech Republic, Canada, Germany, Lebanon, Turkey, Hungary, Norway, Australia, Austria, Belgium, Switzerland
NuCana plc

Recruiting

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Advanced Cancer | Head and Neck Squamous Cell Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Neoplasm Malignant | Pleural... and other conditions

United Kingdom

Clinical Trials on Advanced/ Metastatic Renal Cell Cancer in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations